Arcus Accounts Payable from 2010 to 2025
RCUS Stock | USD 8.40 0.72 7.89% |
Accounts Payable | First Reported 2016-12-31 | Previous Quarter 13 M | Current Value 18 M | Quarterly Volatility 7.4 M |
Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 50.4 M, Interest Income of 54.6 M or Depreciation And Amortization of 6.7 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.
Arcus | Accounts Payable |
Latest Arcus Biosciences' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Arcus Biosciences over the last few years. An accounting item on the balance sheet that represents Arcus Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Arcus Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Arcus Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Arcus Accounts Payable Regression Statistics
Arithmetic Mean | 8,214,039 | |
Geometric Mean | 6,421,814 | |
Coefficient Of Variation | 75.35 | |
Mean Deviation | 5,430,674 | |
Median | 3,867,000 | |
Standard Deviation | 6,189,394 | |
Sample Variance | 38.3T | |
Range | 16.9M | |
R-Value | 0.79 | |
Mean Square Error | 15.5T | |
R-Squared | 0.62 | |
Significance | 0.0003 | |
Slope | 1,026,190 | |
Total Sum of Squares | 574.6T |
Arcus Accounts Payable History
About Arcus Biosciences Financial Statements
Arcus Biosciences shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Arcus Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Arcus Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcus Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Accounts Payable | 18 M | 11.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.